LB Pharmaceuticals Inc Adds Veteran Neuroscience Executive Robert Lenz, M.D., Ph.D. To Board Of Directors

LB Pharmaceuticals Inc, a late-stage biopharmaceutical company developing new treatments for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD), and other neuropsychiatric conditions, announced the appointment of Robert Lenz, M.D., Ph.D., to its Board of Directors.

According to Heather Turner, Chief Executive Officer of LB Pharmaceuticals, the addition of Dr. Lenz comes at a pivotal point for the company as it advances LB-102 through late-stage development across several therapeutic areas. She noted that his extensive background in neuroscience research and development will bring considerable strategic value to the organization.

Sharing his thoughts on joining the board, Dr. Lenz said he is excited to contribute to the company’s momentum and future growth. He expressed confidence in the potential of LB-102, describing it as an investigational therapy that could, if approved, become a key treatment option for psychosis and mood disorders. He emphasized that its profile may offer patients a balanced combination of clinical benefit and tolerability, which remains an important need in psychiatric medicine.

Dr. Robert Lenz brings decades of leadership experience in pharmaceutical research and development. He currently advises several biopharmaceutical companies and most recently served as Executive Vice President and Head of Research and Development at Neumora Therapeutics. Before that, he spent more than ten years at Amgen Inc., where he held multiple senior positions, including Senior Vice President and Head of Global Development.

Earlier in his career, Dr. Lenz held a series of leadership roles at Abbott Laboratories, ultimately becoming Divisional Vice President for Neuroscience, Anesthesia, and Psychiatry Development. Throughout his career, he has overseen the development of several medicines that successfully advanced through regulatory approval. He also serves on both corporate boards and scientific advisory boards across the industry.

Dr. Lenz earned his M.D. and Ph.D. with honors from the University of Maryland School of Medicine and completed his neurology residency at the University of California – Los Angeles. He holds a bachelor’s degree from Dickinson College and has received multiple awards recognizing his innovation and leadership in the pharmaceutical field.